In This Section      
 

Search Results

Title:
EA5142 Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) – A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Protocol Number:
NCTNEA5142
Phase:
Phase III
Physician:
Patrick Forde
Sites:
Johns Hopkins Bayview Medical Center
Johns Hopkins Kimmel Cancer Center in Baltimore
Sibley Memorial Hospital
Purpose:
The purpose of this study is to find if adding the study drug, nivolumab (also known as OPDIVO®), will limit lung cancer from growing back in patients with early stage non-small cell lung cancer.
Eligibility:
Patients with non-small cell lung cancer that has been removed by a surgeon may be eligible.
Treatment:
Eligible participants will be randomized, like the flip of coin, to receive Nivolumab or the current standard of care which is observation. Participants will be routinely monitored by their provider during chemotherapy. All participants will be followed for disease status for up to 10 years.
Population:
Adult
Last Update
03/05/2019 05:03 AM